https://european-biotechnology.com/wp-content/uploads/2024/04/_c__PublicDomainPictures_2pixabay.com.jpg640960Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-03-09 11:38:122024-10-08 09:42:12Collaboration to fight cancer
https://european-biotechnology.com/wp-content/uploads/2024/04/_c__gerald_pixabay.com22.jpg640960Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-03-08 16:28:002024-07-12 13:00:58Noema Pharma AG closes Series B financing
The Supervisory Board of Bayer AG has appointed Roche Pharmaceuticals CEO Bill Anderson (56) as new Chairman of the Management Board of Bayer AG with effect from 1 June 2023.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB.com_Bill_Anderson_new_Bayer_CEO_kl..jpg940936Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2023-03-07 12:13:002024-07-16 17:15:50Bayer AG presents successor für CEO Baumann
https://european-biotechnology.com/wp-content/uploads/2024/04/_c__gerald_pixabay.2com.jpg643960Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-03-02 16:33:012024-07-12 12:58:27Money for AI-powered drug discovery
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
There is increasing interest in delivering a range of drugs via inhalation because of the benefits it can offer patients. Lonza’s Kim Shepard looks at the advantages of pulmonary delivery, and the prospect for inhaled biologics.
https://european-biotechnology.com/wp-content/uploads/2024/04/Kimberley_Shepard_2021_adjusted_extended-2.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-03-01 16:37:352024-04-02 15:34:24Inhalation: the potential for faster onset and fewer side-effects
https://european-biotechnology.com/wp-content/uploads/2024/04/Geldbaum-pixabay.jpg340465Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-03-01 10:08:482024-07-12 12:56:20German HTGF IV fund closes at €493m
British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
Collaboration to fight cancer
Latest NewsThe charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer.
Noema Pharma AG closes Series B financing
Latest NewsNoema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline.
Bayer AG presents successor für CEO Baumann
AppointmentsThe Supervisory Board of Bayer AG has appointed Roche Pharmaceuticals CEO Bill Anderson (56) as new Chairman of the Management Board of Bayer AG with effect from 1 June 2023.
Oculis lists at Nasdaq through SPAC merger
Latest NewsThe eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Money for AI-powered drug discovery
Latest NewsAntiverse Ltd.’s AI identified eight antibodies with therapeutic potential for humans and raised €2.8m in funding for continued in-house development.
Confo Therapeutics and Lilly partner to advance CFTX-1554
Latest NewsDrug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
Inhalation: the potential for faster onset and fewer side-effects
Sponsored PublicationsThere is increasing interest in delivering a range of drugs via inhalation because of the benefits it can offer patients. Lonza’s Kim Shepard looks at the advantages of pulmonary delivery, and the prospect for inhaled biologics.
German HTGF IV fund closes at €493m
Latest NewsThe fourth fund of High-Tech Gründerfonds has reached a final fund volume of €493.8m
Oxford Biomedica changes management
AppointmentsFormer Rentschler-CEO Dr Frank Mathias officially takes up his new position as CEO and board member of Oxford Biomedica at the end of March.
5 Alarm Bio Ltd raises £500K in seed round
Latest NewsBritish anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.